An Israeli company that develops cannabis-based therapeutics has published successful results of a trial testing its diabetic foot relief cream.
Innocan Pharma’s product is a formulation of cannabinoids (chemicals in cannabis that cause drug-like effects in the body’s central nervous system), moisturizers, and vasoconstriction stimulators (which helps the blood vessels become more narrow).
The company says the cream is highly effective in alleviating foot dryness and decreasing the risk of skin cracking, a precursor to bruising and subsequent diabetic complications in individuals with diabetes.
People with diabetes can experience poor blood circulation, meaning that the body’s blood cannot deliver the nutrients needed for cell regrowth in wounded areas – leaving them vulnerable to serious infection that in some cases can be fatal, even from minor cuts and bruises.
Innocan’s seven-day trial tested the cream on individuals living with diabetes and suffering from dry skin. Of the volunteers who participated in the trial, 97 percent reported an immediate improvement in foot skin dryness and an increase in foot skin hydration.
“I am delighted with the outcome of this efficacy trial and the positive influence our product had on the participants,” said Iris Bincovich, CEO of Innocan.
“Our commitment lies in crafting safe and effective solutions that can significantly enhance the quality of life for those in need, and we take immense pride in achieving such encouraging results with our novel foot relief product.”